Quanterix Corporation Stock News

Quanterix (NASDAQ:QTRX) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is -$0.66 and the consensus Revenue Estimate…

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix to Participate in the SVB Leerink Global Healthcare Conference

Leading academic lab harnesses Simoa digital biomarker analysis technology providing up to 1000x greater sensitivity than traditional immunoassays Powering Precision Health 2022 Alzheimer''s podcast announced in recognition of Biomarker Factory launch Quanterix Corporation (NASDAQ: QTRX ), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its Simoa® technology is powering groundbreaking neurodegenerative disease research at the recently launched UK Dementia Research Institute (DRI) Biomarker Factory, where Professor Henrik Zetterberg, Group Leader at UK DRI at University College London (UCL), is leading an effort to develop the next generation of ultrasensitive tests to increase our knowledge of diseases such as Alzheimer''s and other dementias at the earliest possible stages of detection. "Alzheimer''s diagnosis is most often made late in the disease pathology after some level of cognitive impairment has already presented.

BILLERICA, Mass.--(BUSINESS WIRE)--UK Dementia Research Institute Biomarker Factory Powers Alzheimers Disease Breakthroughs with Quanterix Simoa® Technology

Quanterix (QTRX) provides preliminary financial highlights for Q4 and FY 2021 ending December 31, 2021

Quanterix Corp (QTRX) shares closed today at 0.6% above its 52 week low of $34.04, giving the company a market cap of $1B. The stock is currently down 19.3% year-to-date, down 29.8% over the past 12 months, and up 95.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 52.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 17.9% The company's stock price performance over the past 12 months lags the peer average by 3.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference

Wall Street brokerages predict that Quanterix Co. (NASDAQ:QTRX) will post sales of $27.40 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Quanterixs earnings, with the lowest sales estimate coming in at $26.10 million and the highest estimate coming in at $28.85 million. Quanterix reported sales of $26.13 []

Brokerages predict that Quanterix Co. (NASDAQ:QTRX) will announce earnings per share (EPS) of ($0.69) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Quanterixs earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.67). Quanterix posted earnings of ($0.31) per share in the same quarter last []

Quanterix Co. (NASDAQ:QTRX)s share price was up 7.3% during mid-day trading on Friday . The company traded as high as $43.21 and last traded at $43.00. Approximately 6,894 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 334,911 shares. The stock had previously closed at $40.06. Separately, Zacks []

Quanterix (NASDAQ:QTRX) and Cytek BioSciences (NASDAQ:CTKB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends. Institutional and Insider Ownership 82.1% of Quanterix shares are held by institutional investors. Comparatively, 7.3% of Cytek []

Cytek BioSciences (NASDAQ:CTKB) and Quanterix (NASDAQ:QTRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Analyst Recommendations This is a summary of current ratings and price targets for Cytek BioSciences and Quanterix, []

HAMPTON, N.H. , Dec. 9, 2021 /PRNewswire/ -- Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry, announced today that is has raised $300M in capital for its second fund Novalis LifeSciences Investments II, LP. In addition, Paul M. Meister has joined the firm as partner. Novalis LifeSciences is focused on highly innovative Life Science companies. On the occasion of closing the second fund, Marijn E. Dekkers, founder and chairman, said: "This second fund will continue with the investment strategy of Fund I. It will invest in 10-15 companies that are commercializing breakthrough technologies in various segments of the Life Science industry." These segments include biopharma therapeutics, life science tools, genomics, synthetic biology, molecular diagnostics, and agricultural biotechnology all areas with huge unmet needs and exciting opportunities for investors. Some key portfolio companies of Fund I are Ginkgo Bioworks, Cerevel Therapeutics, Decipher Biosciences, Quanterix, and Biotalys, all of which recently became public companies or were acquired.